- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Kim Chi, MD | Authors
Articles
Results of the LATITUDE Trial in High-Risk Metastatic Hormone-Naive Prostate Cancer
June 05, 2017
Video
Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.